Global PSMA-labeled Imaging Ligands Market Strategic Research Report

Scope of the Report

The global PSMA-labeled Imaging Ligands market size is predicted to grow from US$ 2,784 million in 2025 to US$ 12,246 million in 2032; it is expected to grow at a CAGR of 24.2% from 2026 to 2032.

Prostate-specific membrane antigen (PSMA)-labeled ligands refer to small-molecule compounds that target PSMA and are conjugated with diagnostic radionuclides (primarily Gallium-68 and Fluorine-18) for PET imaging, enabling lesion detection, staging evaluation, and pre-therapeutic patient selection in prostate cancer; they do not deliver therapeutic radiation doses and are classified as radiodiagnostic agents, typically serving as a prerequisite step for PSMA-RLT. The PSMA-labeled ligand market is transitioning from early commercialization to rapid expansion, with a global effective addressable market (EAM) of approximately $2.846 billion in 2025 (including $1.679 billion in commercialized market and $1.0–1.5 billion in convertible in-house demand), corresponding to an annual scan volume of 1.5–2.0 million and a CAGR of 23.3%. Growth is primarily driven by the expansion of F-18 industrialized distribution networks in the U.S. and increasing demand for patient selection alongside broader PSMA-RLT penetration, while the Chinese market remains in an early-stage expansion phase driven by infrastructure build-out.

On the supply side, nominal “capacity” is essentially the combination of radiopharmacy network coverage and hospital nuclear medicine processing capabilities, where the Fluorine-18 system offers superior scalability through centralized cyclotron production and distribution networks, while the Gallium-68 system is constrained by generator availability and in-house operational capacity, resulting in a decentralized supply structure. In terms of pricing, F-18 finished radiopharmaceuticals (represented by Pylarify) are priced at approximately $3,000–5,000 per dose, while Ga-68 kit-based usage corresponds to $1,000–3,000 per dose; the industry overall exhibits high gross margins of 70–85% (with higher margins for kits but smaller revenue pools). Downstream applications are highly concentrated in the prostate cancer diagnostic workflow (initial staging → recurrence detection → RLT selection), with demand increasingly shifting toward pre-therapy selection as PSMA-targeted therapies expand. The value chain consists of upstream radionuclide supply (F-18, Ga-68 generators) and ligand synthesis, midstream radiopharmaceutical production and distribution networks (a centralized model led by Lantheus Holdings coexisting with a kit-based model led by Telix Pharmaceuticals), and downstream nuclear medicine departments and imaging centers. The global competitive landscape is characterized by an “F-18 oligopoly + Ga-68 dual-core” structure (industrial distribution dominated by Lantheus Holdings, and kit-based pathways led by Novartis and Telix Pharmaceuticals). The industry is fundamentally in a growth stage where demand has been validated but commercialization penetration remains incomplete, driven by the migration from in-house preparation to industrialized distribution and RLT-driven diagnostic demand, while the key uncertainty lies in logistical delivery radius and nuclear medicine infrastructure constraints on F-18 penetration.

Key Questions Addressed in this Report

What is the 10-year outlook for the global PSMA-labeled Imaging Ligands market?

What factors are driving PSMA-labeled Imaging Ligands market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do PSMA-labeled Imaging Ligands market opportunities vary by end market size?

How does PSMA-labeled Imaging Ligands break out by Type, by Application?

This report presents a comprehensive overview of the global PSMA-labeled Imaging Ligands market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Gallium-68（Ga-68）
• Fluorine-18（F-18）

Segment by Dosage

• Ready-to-use Drug
• Kit-based Radiolabeling

Segment by Application

• Initial Staging
• Biochemical Recurrence
• Theranostics Selection
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global PSMA-labeled Imaging Ligands market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Initial Staging, Biochemical Recurrence, Theranostics Selection evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact